SCHEMBL2942825

SCHEMBL2942825

CC(=O)OCc1cccc(C(=O)C(C(=O)c2cc(F)cc(F)c2)=C2Nc3ccccc3N2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
MAOB P27338 3/20 0.40
MIF P14174 1/20 0.39
RAB9A P51151 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
STAT1 P42224 1/20 0.39
MMP1 P03956 2/20 0.37
MMP2 P08253 2/20 0.37
MMP9 P14780 2/20 0.37
MMP12 P39900 2/20 0.37
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
MRGPRX4 Q96LA9 4/20 0.36
NR4A2 P43354 2/20 0.36
CES2 O00748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942841 0.94 MAOB (0.46) ALDH1A1MAOBMIFRAB9AKDM4E
SCHEMBL2939960 0.85 CES2 (0.35) ALDH1A1RAB9AKDM4EMAPTCES2
SCHEMBL2947464 0.84 CES2 (0.40) RAB9AMAPTCYP2D6MRGPRX4NR4A2
SCHEMBL2945431 0.83 CES2 (0.39) RAB9AMMP1MMP2MMP9MMP12
SCHEMBL2944394 0.81 CES2 (0.41) ALDH1A1MAOBGAAMAPTCES2
SCHEMBL2946902 0.80 FFAR1 (0.40) CES2CES1
SCHEMBL4323510 0.78 CES2 (0.46) CES2CES1
SCHEMBL2944822 0.78 CES2 (0.47) MAOBKDM4EGAAMAPTCYP2D6
Hydrochloric Acid SCHEMBL4325850 0.76 PBRM1 (0.41) ALDH1A1KDM4ECES2CES1NPC1
SCHEMBL2947028 0.75 UNG (0.43) ALDH1A1MAOBRAB9ACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076367-B2 Benzimidazolylidene propane-1,3-dione derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-12-13 US disclosed
US-20100173946-A1 BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2010-07-08 US disclosed
US-7709519-B2 Benzimidazolylidene propane-1,3 dione derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2010-05-04 US disclosed
US-20090018177-A1 Propane-1,3-Dione Derivative or Salt Thereof ASTELLAS PHARMA INC. (JP) 2009-01-15 US disclosed
EP-1752452-A9 PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT Astellas Pharma Inc. (JP) 2007-12-12 EP disclosed
EP-1752452-A1 PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT Astellas Pharma Inc. (JP) 2007-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018177-A1 Propane-1,3-Dione Derivative or Salt Thereof GPER1, GNRHR, AR ALDH1A1 719/4885MAOB 3239/4885MIF 555/4885
US-20100173946-A1 BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF GPER1, GNRHR, AR ALDH1A1 1046/4885MAOB 3161/4885MIF 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.